- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01063972
Smoking Cessation in Rural Hospitals
Centralized Disease Management for Rural Hospitalized Smokers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The proposed study will use a randomized clinical trial design to examine the effectiveness of centralized disease management (CDM) versus counseling alone (C) for smoking cessation. Hospitalized smokers in 30 rural critical access hospitals will be randomly assigned to either CDM (n=303) or C (n=303). Participants in both arms of the study will receive in-hospital smoking cessation counseling via telephone followed by 4 outpatient telephone-based counseling calls. The content and timing of these counseling calls are designed to emulate models of smoking cessation counseling that have been previously shown to be effective for hospitalized smokers. For recipients assigned to CDM, the counseling will be streamlined to allow time on the calls for specific disease management interventions, including screening for contraindications to pharmacotherapy and linking medication choices to the smoker's insurance coverage. After completing calls with CDM participants, the Tobacco Treatment Specialists will coordinate therapy with the patient's health care providers by providing them with brief consultation reports, prepared order sheets for inpatient treatment, and outpatient prescription requests. Six months postdischarge, participants in both groups will be contacted again, and persistent or relapsed smokers will be offered another cycle of the C or CDM intervention.
Assessments will be conducted at baseline and at months 3, 6, and 12. The primary outcome of interest will be biochemically verified 7-day point prevalence abstinence at 12 months. Secondary endpoints include number of quit attempts and number of cigarettes smoked (among continuing smokers), pharmacotherapy utilization, duration of pharmacotherapy utilization, and the extent of discussions with the healthcare provider. We will also examine the marginal cost-effectiveness of the intervention.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hospitalized in a participating rural hospital
- Aged 18 years or older
- Smoke cigarettes on >25 of the last 30 days
- Have a home address and telephone
- Willing to participate in phone assessments
Exclusion Criteria:
- Terminal medical condition with life expectancy <1 year
- Pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Experimental 1
Experimental: 1 Centralized disease management
|
Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider
|
|
Experimental: Experimental 2
Experimental: 2 Counseling alone
|
Counseling (C) arm will receive counseling without the care coordination services.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With 7-day Point Prevalence Abstinence From Cigarettes, Validated
Time Frame: 12 months
|
Participant-reported 7-day point prevalence abstinence from cigarettes, validated by salivary cotinine (< 15ng/ml) or proxy.
Participants who did not respond to the survey were considered current smokers.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With 7-day Point Prevalence Abstinence at 3 Months, Self-reported
Time Frame: 3 months
|
7-day point prevalence abstinence at 3 months, self-reported.
Participants who did not respond were considered smokers.
|
3 months
|
|
Number of Participants With 7-day Point Prevalence Abstinence at 6 Months, Self-reported
Time Frame: 6 months
|
7-day point prevalence abstinence at 6 months, self-reported.
Participants who did not respond were considered smokers.
|
6 months
|
|
Number of Participants With 7-day Point Prevalence Abstinence at 12 Months, Self-reported
Time Frame: 12 months
|
7-day point prevalence abstinence at 12 months, self-reported.
Participants who did not respond were considered smokers.
|
12 months
|
|
Number of Participants Reporting Utilization of Smoking Cessation Pharmacotherapy During First 6 Months
Time Frame: 6 months
|
6 months
|
|
|
Number of Participants Reporting Utilization of Smoking Cessation Pharmacotherapy Between 6 and 12 Months
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Edward Ellerbeck, MD, MPH, University of Kansas Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 5R01CA101963-07 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking Cessation
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
National University of SingaporeRecruitingSmoking &Amp; Tobacco CessationSingapore
-
Nabi BiopharmaceuticalsNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco CessationUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)Completed
-
Heidelberg UniversityPfizerTerminatedSmoking | Smoking Cessation | Tobacco Use CessationGermany
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedSmoking &Amp; Tobacco CessationUnited States
-
Sultan Qaboos UniversityCompletedSmoking Cessation | Tobacco Use Cessation | Smoking PreventionOman
-
The University of Hong KongCompletedSmoking Cessation Counseling Ability | Smoking Cessation Counseling PracticeHong Kong
Clinical Trials on Centralized disease management (CDM)
-
Saint Vincent's Hospital, KoreaKorean Center for Disease Control and Prevention; Hanam City Center for Hypertension...RecruitingHypertension | Diabetes Mellitus | Dyslipidemia | Primary PreventionKorea, Republic of
-
Massachusetts General HospitalCompletedCardiovascular Diseases | Hypertension | Diabetes MellitusUnited States
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
The University of Texas Health Science Center at...Department of Health and Human Services; Centers for Disease Control and Prevention and other collaboratorsCompleted
-
Hiroshima UniversityMinistry of Health, Labour and Welfare, JapanCompletedIschemic StrokeJapan
-
Air Liquide Santé InternationalITEC Services; Lincoln Medical and Mental Health CenterCompletedChronic Obstructive Pulmonary Disease (COPD)France, Spain, Germany, Italy
-
Icahn School of Medicine at Mount SinaiAgency for Healthcare Research and Quality (AHRQ)CompletedCongestive Heart Failure (CHF) | Systolic DysfunctionUnited States
-
Baker Heart and Diabetes InstituteRecruitingHeart Failure | Cognitive Impairment | Dementia | Cognitive Change | Cognitive Decline | Left Ventricular DysfunctionAustralia
-
University of Sao PauloCompleted
-
China-Japan Friendship HospitalHeidelberg University; Peking Union Medical CollegeNot yet recruitingChronic Obstructive Pulmonary Disease | Comorbidities and Coexisting Conditions